Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes
- First Online:
- Cite this article as:
- Harjutsalo, V., Maric, C., Forsblom, C. et al. Diabetologia (2011) 54: 1992. doi:10.1007/s00125-011-2144-2
- 470 Views
This study examined sex-related differences in the cumulative risk of proliferative retinopathy (PR) and end-stage renal disease (ESRD) over 40 years of duration of type 1 diabetes according to age at diabetes onset.
We assessed 4,416 patients from the Finnish Diabetic Nephropathy Study population. Kaplan–Meier analysis was used to provide cumulative incidence rates and Cox regression analyses for HRs.
There were no sex-related differences in the cumulative incidence of ESRD in patients diagnosed with type 1 diabetes between 0 to 4 and 5 to 9 years. Thereafter the risk started to diverge. The cumulative incidence of ESRD in patients diagnosed between 10 to 14 and ≥15 years was 17.4% (95% CI 13.4–21.2) and 13.0% (9.6–16.2) respectively in women, while in men it was 32.2% (28.0–36.1) and 24.6% (20.8–28.1) respectively. The respective HRs were (onset at 10 to 14 years) 1.9 (p < 0.0001) and (onset at ≥15 years) 1.8 (p < 0.001), respectively. There was no difference in the risk of PR between men and women diagnosed between 0 and 4 years of age, but progressive sex-related differences in the cumulative incidence of PR were observed with increasing age at onset. The HRs for men in the age-at-onset groups 5 to 9, 10 to 14 and ≥15 years of age were 1.3 (95% CI 1.0–1.6), 1.3 (1.1–1.6) and 2.1 (1.6–2.6) compared with women in these groups, respectively.
The difference between the sexes with regard to risk of diabetic microvascular complications is highly dependent on the age at onset of diabetes. The risk of ESRD and PR risk doubled in men compared with women when age at onset was ≥15 years.
KeywordsAge at onsetDiabetic nephropathyEnd-stage renal disease (ESRD)Hormonal changesProliferative retinopathySexType 1 diabetes
End-stage renal disease
Finnish Diabetic Nephropathy Study
Most previous studies suggest that male sex increases the risk of microvascular complications associated with type 1 diabetes, especially that of diabetic nephropathy. In adult men, development and progression of albuminuria is greater than in age-matched women with type 1 diabetes [1, 2]; however, the impact of different ages at onset of diabetes was not taken into account in these studies. Some data suggest that, in addition to sex, the age at onset of type 1 diabetes is also an important determinant of the overall risk of developing diabetic microvascular complications [3, 4]. But the question of whether age at onset of diabetes has a similar impact on the risk of microvascular complications in men as in women is inadequately studied. Moreover, most previous studies are related to diabetic nephropathy or microalbuminuria, and have found that male sex is a risk factor [5, 6]. However, studies on sex or age at onset in relation to diabetic retinopathy are sparse and controversial [7–9]. Finally, very few studies have investigated the interaction between sex and age at onset with regard to any microvascular complication [3, 4].
Several studies have shown that diabetic microvascular complications, specifically, retinopathy and diabetic nephropathy, rarely develop before puberty [3, 4, 10–13]. While the relatively short period of time between diagnosis of type 1 diabetes and onset of puberty may explain why complications rarely develop before puberty, it is likely that more physiological reasons exist for this observation. Interestingly, the onset of puberty itself greatly accelerates the development of microvascular disease associated with retinopathy [14, 15] and diabetic nephropathy [15, 16] in type 1 diabetes patients. Poor glycaemic control during puberty, which is related to poor compliance with diet and insulin dosage, is thought to contribute to the risk of long-term microvascular complications . However, other endocrine changes during puberty, such as growth and sexual maturation, may also influence the development and progression of end-organ complications that are associated with type 1 diabetes later in life.
Boys and girls reach puberty at different ages and undergo different biological changes during their sexual maturation . It is therefore conceivable that long-term microvascular complications, the risk of which is accelerated by puberty, may be sex-dependent. Studies that have examined the impact of sex on the development and progression of diabetic end-organ complications, as well as on type 1 diabetes as such, have reported conflicting findings. In most populations studied, the incidence of type 1 diabetes was similar in girls and boys, increasing with age and peaking at puberty in both sexes [19–21]. After puberty, however, the incidence of type 1 diabetes remains high in young adult men, but decreases in young women [20, 22, 23]. Thus, the aim of the present study was to examine the long-term impact of sex on the risk of developing proliferative retinopathy (PR) and end-stage renal disease (ESRD) in adulthood according to age at onset of type 1 diabetes.
The data for the analyses presented are derived from the Finnish Diabetic Nephropathy Study (FinnDiane). FinnDiane is a nationwide, comprehensive multicentre study, designed to identify genetic and environmental risk factors for diabetic complications, with special emphasis on diabetic nephropathy in patients with type 1 diabetes. A detailed description of the FinnDiane study recruitment protocol has been previously described . In brief, eligible patients recruited into the study were those with onset of type 1 diabetes at the age of 40 years or less and in whom insulin treatment was initiated within 1 year of diagnosis. An additional criterion for selection was C-peptide levels ≤0.3 nmol/l. For a list of physicians and nurses at each of the FinnDiane centres participating in patient recruitment and characterisation, see electronic supplementary material (ESM).
At baseline patients underwent a thorough clinical examination that took place in conjunction with a regular visit to the attending physician. Details of clinical characteristics of patients, including age at diagnosis of diabetes, PR and ESRD, and laboratory measurements were obtained from medical files by the attending physician using a standardised questionnaire. Follow-up started at the time of diagnosis of diabetes and ended at the time of diagnosis of PR or ESRD. Patients without these complications contributed to follow-up until their last follow-up visit, the latest screening of their medical files or until their death.
The ethics committees of all participating centres approved the study protocol. Written informed consent was obtained from each patient and the study was performed in accordance with the Declaration of Helsinki as revised in the year 2000.
Definition of PR and ESRD
Finland has a nationally organised diabetes care system and according to the national management guidelines, all patients with type 1 diabetes of 5 years duration and longer are screened for retinopathy approximately every 2nd year. The screenings are performed by ophthalmoscopy followed by fundus photography, based on which candidates for laser treatment are selected. In this study, laser treatment was considered as evidence of PR. Although laser treatment is also used for clinically significant macular oedema, most patients receiving laser treatment in this study received it for PR. In a separate subset of the FinnDiane patient population we saw that most of those patients receiving laser treatment for macular oedema later also received laser treatment for PR. ESRD was defined as dialysis treatment or having received a kidney transplant. The analysis for PR included 3,828 patients, that for ESRD 4,416 patients.
For the analysis, the patients were divided into four groups according to the age at onset of diabetes, i.e.: 0–4, 5–9, 10–14 and ≥15 years of age. Sex-related differences in the risk of microvascular complications were studied within each age-at-onset group. The cumulative incidence of PR and ESRD was estimated using the Kaplan–Meier method. Deaths without event were treated as censored observations. Analyses were conducted stratifying the data according to the age at onset of diabetes. Differences between the groups were tested using the logrank test. The HRs were estimated using Cox proportional hazards modelling. Interaction between sex and age at onset was tested. Because patients with ESRD frequently have PR, analyses of risk of PR were also conducted excluding patients with ESRD. All analyses were performed using a software package (SAS 9.2; SAS Institute, Cary, NC, USA).
Number of men and women diagnosed with PR and ESRD according to the age at onset of type 1 diabetes
Duration of diabetes (years)
Patients, n (%)
Patients, n (%)
PR, median (IQR)
ESRD, median (IQR)
Sex-related differences in the cumulative risk of ESRD
Sex-related differences in the 40 year cumulative risk of PR and ESRD according to age of diagnosis of type 1 diabetes
PR analysis with ESRD patients excluded
95% CI for HR
95% CI for HR
95% CI for HR
Interestingly, if all age-at-onset groups were pooled, sex-related differences were not noticeable over 30 years of duration of diabetes. The 30 year cumulative risk of ESRD was 9.6% (95% CI 8.1–11.0) in women and 11.5% (95% CI 10.0–12.9) in men, HR = 1.23 (p = 0.07).
Sex-related differences in the cumulative risk of PR
When data analysed excluded patients who also had ESRD, the sex-related difference remained similar (Table 2). In fact, in the oldest age-at-onset group, the sex-related difference was even strengthened.
This study shows that the risk of diabetic microvascular complications, in the form of PR and ESRD, over 40 years of type 1 diabetes duration is highly dependent on age at onset of diabetes and on sex. Interestingly, when all age-at-onset groups were pooled, the sex-related difference in the risk of ESRD was not noticeable at 30 years of disease duration, only becoming noticeable at 40 years of duration. In essence, only stratification by age at onset and a long enough follow-up time revealed the sex-related difference. This sex-related divergence in ESRD was evident at age at onset of 10 years and older; in PR, it was evident when age at onset was between 5 and 9 years, and increased thereafter.
While male sex is thought to be a risk factor for development of diabetic microvascular complications [1, 2], the majority of epidemiological studies commonly group women and men together in the analyses, thus potentially masking the impact of sex on disease development and progression. Our study shows the importance of considering age at onset of diabetes revealing sex-related differences. Specifically, this study shows that sex-related differences in the long-term risk of PR first became evident in patients diagnosed with type 1 diabetes at the age of 5 to 9 years, becoming more pronounced with increasing age at disease onset. In the case of ESRD, sex-related differences were not evident in patients diagnosed before 10 years of age, but did emerge in patients with pubertal and adult onset of type 1 diabetes. These observations suggest that the critical period of sexual maturation and permanent hormonal changes are permissive to development of long-term complications, this being more true of men than women. We do not believe that these differences are related to differences in glycaemic control, as the mean HbA1c value based on one cross-sectional measurement was similar in men and women, i.e. 8.38% vs 8.45% (data not shown).
Findings from the present study support previous reports that the male sex is a risk factor for ESRD [1, 2]. However, the impact of sex on the risk of retinopathy is rarely reported and the available data are conflicting [25, 26]. Some studies have reported that men have a greater risk of diabetic retinopathy, but not PR [9, 25]. Our study shows that male sex is a risk factor for PR and that this risk is stronger with increasing age at onset of diabetes.
In agreement with our study, a recent nationwide population-based Swedish study found no sex-related difference in the risk of ESRD in patients diagnosed under age of 10 years . This study also failed to find a significant difference between sexes when age at onset was between 10 and 19 years. However, thereafter sex-related differences did emerge. It should be noted that that study reported cumulative incidence only over 30 years of diabetes, while our study shows that sex-related differences do not become noticeable until 40 years of diabetes duration. Thus, a longer duration of diabetes appears to be necessary for ESRD to develop in many predisposed patients. Taken together, these observations underscore the impact of sex in the risk of ESRD.
One mechanism underlying the sex-related difference in the development of microvascular complications may be epigenetic modifications. It is known that sex hormones and high glucose trigger epigenetic modifications, thus regulating gene expression without changing DNA sequences [28, 29]. Changes in the hormonal profile before and after puberty, and prior to or after diagnosis of diabetes, may also differentially trigger epigenetic modifications. It is therefore conceivable that differential timing and order of factors causing epigenetic modifications may play a key role in determining the risk of microvascular complications in men and women. Bearing this in mind, sex-related differences in the development of microvascular complications according to age at onset may be explained as follows. First, when men and women have age at onset below 5 years, no differences emerge regarding lifetime risk of PR and ESRD. Thus, exposure to hyperglycaemia prior to hormonal changes equally modifies predisposing genes in both sexes, leading to a similar risk pattern in both sexes. Second, when diabetes starts at the age of 5 to 9 years, it coincides with pre-pubertal changes. Simultaneous occurrence of diabetes and these pre-pubertal hormonal changes may thus lead to different risk profiles in men and women. Third, hormonal changes during puberty leading to sexual maturation may further differentiate the risk profiles in men and women. Finally, if pre-pubertal and pubertal hormonal changes occur before onset of type 1 diabetes and glycaemic exposure, this seems to favour women.
Our observations suggest that the much discussed pubertal onset of diabetes as a risk factor for long-term diabetic organ complications is specific to men, but that early age of development of diabetes poses similar risk for men and women. Also in post-pubertal onset of type 1 diabetes, the sex-related difference remains, but favours women. Puberty is characterised by several hormonal and metabolic changes, including the acceleration and cessation of somatic growth and onset of reproductive capacity. Our study suggests that these changes appear to permit the development of organ complications later in life, particularly in men. Hormones involved in the control of somatic growth and reproduction during puberty, including growth hormone and insulin-like growth factor, have already been implicated in the development of diabetic microvascular complications .
Levels of testosterone and sex-hormone-binding globulin (SHBG) have been linked to the risk of diabetic nephropathy and diabetic retinopathy. It has consistently been found that testosterone and SHBG have an effect, but the direction of the effect seems to vary from study to study. In some studies reduced levels of testosterone, while in other studies increased levels of testosterone, were found to correlate with decline in microalbuminuria or diabetic nephropathy [31, 32]. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy participants who progressed to PR or preproliferative retinopathy had lower levels of serum SHBG than controls . Moreover, serum testosterone concentrations were significantly higher in male diabetic participants with PR . Chaurasia et al. also found higher testosterone levels in patients with proliferative diabetic retinopathy .
The fact that women appear to have a lower overall cumulative risk of complications than men suggests that female sex is a protective factor against the development of microvascular complications. Several experimental studies have demonstrated a renoprotective role of exogenous oestrogens in models of type 1 diabetic retinopathy and nephropathy [36–39]. However, an experimental model of type 1 diabetes has also, however, shown that relative balance, rather than the absolute levels of sex hormones, correlates with conditions associated with diabetic complications .
Interestingly, the attained chronological age at which the sex-related differences in the risk of both ESRD and PR first become apparent was around 32 to 37 years. It is, of course, possible that changes developing around the age of 32 to 37 years are not entirely related to diabetes, but rather biological changes that are specific to men at this time in life.
To our knowledge, this is the first study to report sex-related differences in the 40 year cumulative risk of PR and ESRD based on age at onset of type 1 diabetes. One of its major strengths is the large number of patients included in the analysis and their long-term (40 years) follow-up. The main limitation is that FinnDiane is not, by strict definition, a population-based study, although it is a large nationwide study. Thus, patients who died before recruitment never reached this cohort, leading to selection of surviving patients only. However, confirmation of our results comes from a population-based study from Sweden , and we found the same pattern with longer follow-up time.
In summary, our study suggests that the difference between the sexes with regard to long-term risk of developing diabetic microvascular complications is highly dependent on the age at onset of type 1 diabetes. These data suggest that, in addition to the classical risk factors for diabetic retinopathy and nephropathy, sex-specific initiation of diabetes interventions may be necessary for effective prevention from complications in these patients.
The authors would like to acknowledge all of the physicians and nurses at each of the FinnDiane centres participating in patient recruitment and characterisation (see ESM). This research was supported by grants from the Folkhälsan Research Foundation, Wilhelm and Else Stockmann Foundation, Liv och Hälsa Foundation and The Finnish Medical Society (to P.-H. Groop), and the Research Career Enhancement Award from the American Physiological Society (to C. Maric).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.